BioSpace News Archive

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, announced the successful completion of patient enrollment for the pancreatic cancer cohort in the Phase 1b/2a CENDIFOX trial.

Aphaia Pharma announced that it has completed enrollment in the second arm of its Phase 2 trial, which is evaluating the safety and efficacy of two separate doses of Aphaia’s formulation, or their respective placebos, twice per day to induce weight loss in individuals with obesity.

Sharps Technology, Inc. received a signed $30 million purchase order from Nephron Pharmaceuticals, representing their first 12 months of syringe purchase commitments.

ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.

Asahi Kasei has announced that in April 2024 it began selling a membrane system to produce WFI, a type of sterile water that is used for the preparation of injections.

Nancy, France, June 11, 2024 - Banook Group, global provider of technology and services for clinical trial operators, today announces two strategic acquisitions that enhance its offerings in central imaging and eCOA.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the first healthy volunteers have been dosed in the Phase 1a trial of VYN202.

Positron Corporation (“Positron” or the “Company”) (OTC: POSC) is pleased to announce it has secured exclusive rights for the North American market to sell/distribute the NeuSight PET-CT 64 slice scanner through a business cooperation agreement with Neusoft Medical Systems’ subsidiary, Shenyang Intelligent Neuclear Medical Technology Co.

Glucotrack, Inc. announced that its implantable continuous glucose monitor has successfully completed a 60-day long-term preclinical study demonstrating the feasibility of glucose monitoring in the epidural space.

Jumpcode Genomics and Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., announced the companies have settled their patent dispute and have partnered to bring together their combined foundational IP in the field of targeted depletion of undesired transcripts such as ribosomal RNAs from NGS libraries using CRISPR-based technology.